2020-11-17 08:41:50 ATNF 180 Life Sciences
11/17/20 11/1708:41 11/17/2008:41 | 180 Life Sciences CEO expects operating expenses to remain low relative to peers180 Life Sciences Corp. released the following letter to stockholders from its CEO Dr. James Woody. The letter read in part, "On the heels of the November 9, 2020, closing of our merger with KBLM Merger Corp IV, resulting in 180 Life Sciences now being a stand-alone publicly traded company and its common stock being listed on The NASDAQ Capital Market under the symbol "ATNF", I wanted to take this opportunity to personally communicate with you. It goes without saying that I appreciate your support in helping us get to where we are today and want to update you on our planned path moving forward...I'd like to now tell you a little about our exciting pipeline which includes three clinical programs addressing the following indications: Early Dupuytren's contracture, a fibrotic disease of the hand, which is in Phase 2b/3, with results expected in 2H 2021. Dupuytren's disease is estimated to impact over 11 million Americans, and about the same number in the European Union. Our trial is focused on treating early and preventing the progress of the disease to avoid the hand contracture disability. This project is entirely grant funded. Frozen shoulder, with a grant to initiate the clinical study recently awarded by the National Institute of Health Research, U.K. Due to COVID-19, we plan to start the trial in Q3 2021. Again, we plan to try and avoid the pain and disability associated with Frozen Shoulder by treating early. Post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population, most commonly following lengthy anesthesia during hip fracture repair or after CABG. We hope to be able to reduce or prevent this dysfunction. Additionally, our pre-clinical discovery programs include: A program focused on the development of unique, Food and Drug Administration-approved, pharmaceutical-grade oral synthetic cannabidiol analogs to treat pain that is specifically focused on arthritis. This project is run in Israel and Oxford, England. We are working with one of the foremost authorities on Cannabis chemistry and the discoverer of the body's own "cannabinoids", Prof Raphael Mechoulam. To optimize uptake we are working with an expert in cannabinoid drug delivery, Prof Avi Domb in Jerusalem, Israel. The alpha7nAChR program, which aims to develop alpha7nAChR agonists for the treatment of inflammatory diseases, initially ulcerative colitis induced after cessation of smoking. We look forward to the results of our Phase 2b/3 study on Dupuytren's contracture, a disease that impacts a large total addressable market estimated to comprise over 22 million in the US and EU. We believe that if we are able to successfully commercialize this drug, of which there can be no assurance, it has the potential to generate significant revenues for the Company. It is important to note that our business model itself is unique for a biotech company. Almost all our clinical studies to date have been funded in full through grants. While ultimately, we intend to fund some studies internally, we anticipate our operating expenses will remain low relative to our peers. There are many advantages of doing clinical development mostly with academic leaders, both in cost, efficiency and credibility. I'd like to close by telling you why I took the role as CEO and what my personal goal is for the Company. My goal and the goal of the other members of management is to build stockholder value by developing world leading products to solve unmet medical needs. As management and insiders currently own over 50% of the Company, we believe our goals are directly aligned with the stockholders of the Company. Many members of our management team have not taken a salary to date. Future compensation will be conservative, favoring equity over cash." |
---|
Periodicals
|
SVF Investment Corp. 3 in talks to bring Mapbox public, Sky News says »
11:18 04/23/21 04/2311:18 04/23/2111:18
SVFC
SVF Investment Corp. 3
SoftBank
SVF Investment Corp. 3… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
|
NASDAQ market internals summary »
11:17 04/23/21 04/2311:17 04/23/2111:17
$NSD
NASDAQ Market Internals
Volume is above average… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
SilverCrest Metals price target raised to C$14.50 from C$14 at National Bank »
11:16 04/23/21 04/2311:16 04/23/2111:16
SILV
SilverCrest Metals
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Technical Analysis
| Volume is average for… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Marathon Gold price target raised to C$3.50 from C$3.25 at National Bank »
11:15 04/23/21 04/2311:15 04/23/2111:15
MGDPF
Marathon Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Maverix Metals price target raised to C$7.75 from C$7.50 at National Bank »
11:15 04/23/21 04/2311:15 04/23/2111:15
MMX
Maverix Metals
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Franco-Nevada price target raised to C$190 from C$185 at National Bank »
11:14 04/23/21 04/2311:14 04/23/2111:14
FNV
Franco-Nevada
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Fortuna Silver Mines price target raised to C$12.50 at National Bank »
11:14 04/23/21 04/2311:14 04/23/2111:14
FSM
Fortuna Silver Mines
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Teva launches generic version of Casana suppositories »
11:10 04/23/21 04/2311:10 04/23/2111:10
TEVA
Teva
Teva Pharmaceuticals USA… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Aya Gold & Silver price target raised to C$9 from C$7.25 at National Bank »
11:07 04/23/21 04/2311:07 04/23/2111:07
MYAGF
Aya Gold & Silver
National Bank analyst Don… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Wesdome Gold Mines price target raised to C$12.50 from C$12 at National Bank »
11:07 04/23/21 04/2311:07 04/23/2111:07
WDOFF
Wesdome Gold Mines
National Bank analyst Don… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Yamana Gold price target raised to C$7.25 from C$7 at National Bank »
11:07 04/23/21 04/2311:07 04/23/2111:07
AUY
Yamana Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
General news
|
U.S. new home sales sharply beat estimates »
11:05 04/23/21 04/2311:05 04/23/2111:05
$ECON
Economic Data
U.S. new home sales… Story temporarily locked. ShowHide Related Items >><< |
Options
|
Coty call volume above normal and directionally bullish »
11:05 04/23/21 04/2311:05 04/23/2111:05
COTY
Coty
Bullish option flow… Story temporarily locked. ShowHide Related Items >><<
|
General news
| FX Action: USD-JPY hit… Story temporarily locked. ShowHide Related Items >><< |
Hot Stocks
|
3M says MA MicroGrind wheels found to infringe on German Utility Model »
11:04 04/23/21 04/2311:04 04/23/2111:04
MMM
3M
The German District Court… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
OceanaGold price target lowered to C$3 from C$3.25 at National Bank »
11:02 04/23/21 04/2311:02 04/23/2111:02
OCANF
OceanaGold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Northern Genesis Acquisition reports stockholders approve combination with Lion »
11:02 04/23/21 04/2311:02 04/23/2111:02
NGA
Northern Genesis Acquisition
Lion Electric
Northern Genesis… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Goldman Sachs communications tech analyst holds analyst/industry conference call »
10:55 04/23/21 04/2310:55 04/23/2110:55
Communications Technology… Story temporarily locked. |
Recommendations
|
New Gold price target lowered to C$3 from C$3.25 at National Bank »
10:53 04/23/21 04/2310:53 04/23/2110:53
NGD
New Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Equinox Gold price target lowered to C$15.25 from C$15.50 at National Bank »
10:52 04/23/21 04/2310:52 04/23/2110:52
EQX
Equinox Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Eldorado Gold price target lowered to C$18 from C$19 at National Bank »
10:52 04/23/21 04/2310:52 04/23/2110:52
EGO
Eldorado Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Dundee Precious Metals price target raised to C$12.50 at National Bank »
10:51 04/23/21 04/2310:51 04/23/2110:51
DPMLF
Dundee Precious Metals
National Bank analyst Don… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Centerra Gold price target raised to C$18.50 from C$17.50 at National Bank »
10:50 04/23/21 04/2310:50 04/23/2110:50
CGAU
Centerra Gold
National Bank analyst… Story temporarily locked. ShowHide Related Items >><<
|
Options
|
Ford put volume 5x normal including correction »
10:50 04/23/21 04/2310:50 04/23/2110:50
F
Ford
Ford put volume 5x normal… Story temporarily locked. ShowHide Related Items >><<
|